Cardinal Health has agreed to sell its China business to Shanghai Pharma for $557 million in cash.
Launched for lung cancer awareness month in November, the “tALK+” (Talk Positive) campaign focuses on the ALK-positive form of lung cancer.
Pfizer bowed out of a troubled joint venture with China's Hisun Pharma, which sells branded generic drugs in China.
Takeda, along with Lundbeck and Advocate Health Care, will study an app to track and measure patients’ experience on antidepressant therapies.
Teva is reportedly looking to form a Chinese JV, Lupin was hit with an FDA warning letter, EOC Pharma raised $32 million in series B and more.
The FDA has slapped a warning letter on a Chinese company that shipped multiple lots of an OTC product to the U.S. that contained the wrong API.
Takeda's dengue vaccine induced sustained antibody responses in children, topline phase 2 data showed.
Teva, the world's largest generics maker, is looking to form a Chinese joint venture with local company Guangzhou Pharma.
Daiichi reported results from a troubled cancer trial and formed a deal with Glycotope, Samsung BioLogics reported operating profits.
Biocon has seen its earnings hit by FDA and EU regulatory issues at its Indian plant that makes the biosimilars it and partner Mylan have developed.